Inhibrx Biosciences (INBX) Retained Earnings (2023 - 2025)
Historic Retained Earnings for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$213.4 million.
- Inhibrx Biosciences' Retained Earnings fell 26603.77% to -$213.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.4 million, marking a year-over-year decrease of 26603.77%. This contributed to the annual value of -$106.1 million for FY2024, which is 8270.72% up from last year.
- Per Inhibrx Biosciences' latest filing, its Retained Earnings stood at -$213.4 million for Q3 2025, which was down 26603.77% from -$178.1 million recorded in Q2 2025.
- Inhibrx Biosciences' Retained Earnings' 5-year high stood at -$14.4 million during Q2 2024, with a 5-year trough of -$613.7 million in Q4 2023.
- Over the past 3 years, Inhibrx Biosciences' median Retained Earnings value was -$149.4 million (recorded in 2025), while the average stood at -$190.5 million.
- Its Retained Earnings has fluctuated over the past 5 years, first skyrocketed by 8270.72% in 2024, then crashed by 113654.79% in 2025.
- Quarter analysis of 3 years shows Inhibrx Biosciences' Retained Earnings stood at -$613.7 million in 2023, then surged by 82.71% to -$106.1 million in 2024, then plummeted by 101.07% to -$213.4 million in 2025.
- Its Retained Earnings was -$213.4 million in Q3 2025, compared to -$178.1 million in Q2 2025 and -$149.4 million in Q1 2025.